Legal & General Group Plc Reduces Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Legal & General Group Plc decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.5% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 743,027 shares of the biopharmaceutical company’s stock after selling 27,332 shares during the period. Legal & General Group Plc’s holdings in Regeneron Pharmaceuticals were worth $573,520,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. WPG Advisers LLC grew its stake in shares of Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 25 shares during the last quarter. Board of the Pension Protection Fund purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $31,000. Entrust Financial LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $32,000. Torren Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $38,000. Finally, FNY Investment Advisers LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $38,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $638.88 on Tuesday. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11. The stock’s 50 day simple moving average is $729.30 and its two-hundred day simple moving average is $745.72. The firm has a market cap of $67.54 billion, a PE ratio of 15.57, a P/E/G ratio of 1.41 and a beta of 0.30.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. During the same quarter in the prior year, the firm posted $8.22 EPS. The business’s quarterly revenue was up 19.0% compared to the same quarter last year. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.25 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th will be given a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.6%. The ex-dividend date is Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.16%.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $705.24, for a total value of $70,524.00. Following the sale, the director owned 17,503 shares in the company, valued at approximately $12,343,815.72. This represents a 0.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on REGN. Royal Bank Of Canada dropped their price target on Regeneron Pharmaceuticals from $762.00 to $707.00 and set a “sector perform” rating on the stock in a research note on Monday, May 18th. Morgan Stanley upped their target price on Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a research report on Friday, April 10th. Oppenheimer reissued an “outperform” rating and set a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, February 2nd. Citigroup cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $900.00 to $700.00 in a research note on Monday, May 18th. Finally, Leerink Partners restated a “market perform” rating and set a $641.00 price objective (down from $792.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, May 18th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $792.65.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.